Owlet Announces Third Quarter 2021 Financial Results
Owlet, Inc. (NYSE: OWLT) reported record revenues of $31.5 million for Q3 2021, marking a 48.8% year-over-year increase and a 26.3% sequential rise from Q2 2021. In the first three quarters, total revenues reached $78.4 million, surpassing the full-year 2020 figure. Despite strong growth, the company faced challenges with an operating loss of $13.8 million and a net loss of $34.5 million. The gross margin was 47.2%, slightly down from Q2 2021. Owlet is working with the FDA on regulatory matters related to the Smart Sock, while also planning the launch of a new baby sleep monitor.
- Record Q3 revenues of $31.5 million, a 48.8% increase from Q3 2020.
- Total revenues of $78.4 million for the first three quarters of 2021, exceeding 2020 full-year revenues.
- International expansion with launches in France and Switzerland.
- Operating loss of $13.8 million compared to $1.1 million in Q3 2020.
- Net loss of $34.5 million, significantly higher than a net loss of $1.5 million in Q3 2020.
- Gross margin decreased sequentially from Q2 2021, impacted by supply chain issues.
Third Quarter Highlights
-
Generated record revenues of
$31.5 million 48.8% increase from the third quarter of 2020, and a26.3% sequential increase from the second quarter of 2021. -
Produced revenues for the first three quarters of 2021 of
$78.4 million -
Advanced Owlet’s international commercial strategy, officially launching in
France andSwitzerland during the third quarter. - Launched the Smart Sock Plus internationally, which can be used in children up to five years old, significantly expanding Owlet’s potential relationship with families.
“We had a strong third quarter at Owlet, with our highest-ever revenues and continued international expansion, including launching into
Workman continued, “Since receiving the FDA Warning Letter and taking prompt action to address its concerns, we have been in ongoing, collaborative discussions with the FDA on a path forward for our medical device application for the Smart Sock. We are also in communication with our ecosystem of partners about what this means. Additionally, our team is working in parallel with our partners to announce a new consumer baby sleep monitor in the fourth quarter of this year. We look forward to sharing more on that soon.”
Financial Results for the Third Quarter Ended
Revenues were
The cost of revenues for the quarter ended
Operating expenses for the quarter ended
Operating loss and net loss for the quarter ended
EBITDA loss for the third quarter of 2021 was
Adjusted EBITDA loss for the third quarter of 2021 was
Net loss per share for the quarter ended
Financial Outlook
Given the Smart Sock’s near-term regulatory status, the Company’s previously announced suspension of shipping of the Smart Sock in
Conference Call and Webcast information
Owlet will host a conference call and audio webcast today at
Domestic: |
|
|
|
(844) 200-6205 |
Domestic Local: |
|
|
|
(646) 904-5544 |
All Other: |
|
|
|
(929) 526-1599 |
Access Code: |
|
|
|
771407 |
Parties wishing to access the call via webcast should use the link in the Investors section of the Owlet website at investors.owletcare.com.
A replay of the webcast will be available in the Investors section of the website approximately 30 minutes after the conclusion of the call. Parties wishing to listen to the replay by phone may do so by dialing (866) 813-9403 or (929) 458-6194 (US), and +44 204 525-0658 (International) and referencing access code 643671.
About
Owlet was founded by a team of parents in 2012. Owlet’s mission is to empower parents with the right information at the right time, to give them more peace of mind and help them find more joy in the journey of parenting. Owlet’s digital parenting platform aims to give parents real-time data and insights to help parents feel calmer and more confident. Owlet believes that every parent deserves peace of mind and the opportunity to feel their well-rested best. Owlet also believes that every child deserves to live a long, happy, and healthy life, and is working to develop products to help further that belief. For more information about Owlet, please visit www.owletcare.com.
Forward-Looking Statement Disclaimer
Certain statements, estimates, targets and projections in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Owlet’s future financial or operating performance. For example, statements relating to the regulatory status of Owlet’s products and its plans for the launch of a wellness product and timing thereof are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Owlet and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Owlet’s competition; the regulatory pathway for Owlet products and responses from regulators, including the
Non-GAAP Financial Measures
This press release includes references to financial measures that are not presented in accordance with generally accepted accounting principles in
The Company’s non-GAAP financial measures should not be considered as an alternative to net loss or net loss per share as a measure of financial performance or any other performance measure derived in accordance with GAAP, and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. EBITDA is defined as net loss adjusted for income tax provision, interest expense, interest income, and depreciation and amortization. Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, interest income, depreciation and amortization, preferred stock mark-to-market adjustments, stock-based compensation, transaction costs, loss on extinguishment of debt, and gain on loan forgiveness. EBITDA margin is defined as EBITDA divided by revenues. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenues. Adjusted net loss is defined as net loss adjusted for non-recurring interest expense, stock-based compensation, transaction costs, preferred stock and common stock warrant liability adjustments, loss on extinguishment of debt, and gain on loan forgiveness. Adjusted loss per share is defined as Adjusted net loss divided by weighted-average shares of common stock.
The Company presents these non-GAAP financial measures because management believes that these measures assist investors and analysts in comparing the Company’s operating performance across reporting periods on a consistent basis by excluding items that management does not believe are indicative of the Company’s ongoing operating performance. Investors are encouraged to evaluate these adjustments and the reasons the Company considers them appropriate for supplemental analysis. In evaluating the Company’s non-GAAP financial measures, investors should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in the Company’s presentation of Company’s non-GAAP financial measures. The Company’s presentation of Company’s non-GAAP financial measures should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. There can be no assurance that the Company will not modify the presentation of the Company’s non-GAAP financial measures in future periods, and any such modification may be material. In addition, the Company’s non-GAAP financial measures may not be comparable to similarly titled measures used by other companies in the Company’s industry or across different industries.
Financial Tables
|
||||||||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Revenues |
|
$ |
31,505 |
|
|
$ |
21,169 |
|
|
$ |
78,354 |
|
|
$ |
54,405 |
|
Cost of revenues |
|
|
16,624 |
|
|
|
11,344 |
|
|
|
37,272 |
|
|
|
28,696 |
|
Gross profit |
|
$ |
14,881 |
|
|
$ |
9,825 |
|
|
$ |
41,082 |
|
|
$ |
25,709 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
General and administrative |
|
|
9,250 |
|
|
|
3,173 |
|
|
|
22,516 |
|
|
|
8,593 |
|
Sales and marketing |
|
|
13,072 |
|
|
|
5,041 |
|
|
|
26,759 |
|
|
|
13,101 |
|
Research and development |
|
|
6,320 |
|
|
|
2,730 |
|
|
|
14,269 |
|
|
|
7,634 |
|
Total operating expenses |
|
$ |
28,642 |
|
|
$ |
10,944 |
|
|
$ |
63,544 |
|
|
$ |
29,328 |
|
Operating loss |
|
$ |
(13,761 |
) |
|
$ |
(1,119 |
) |
|
$ |
(22,462 |
) |
|
$ |
(3,619 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Gain on loan forgiveness |
|
|
- |
|
|
|
- |
|
|
|
2,098 |
|
|
|
- |
|
Interest expense, net |
|
|
(477 |
) |
|
|
(377 |
) |
|
|
(1,378 |
) |
|
|
(1,010 |
) |
Interest expense from contingent beneficial conversion feature |
|
|
(26,061 |
) |
|
|
|
|
|
(26,061 |
) |
|
|
|
||
Preferred stock warrant liability adjustment |
|
|
- |
|
|
|
1 |
|
|
|
(5,578 |
) |
|
|
9 |
|
Common stock warrant liability adjustment |
|
|
5,792 |
|
|
|
- |
|
|
|
5,792 |
|
|
|
- |
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
- |
|
|
|
(182 |
) |
|
|
(172 |
) |
Other income (expense), net |
|
|
66 |
|
|
|
(6 |
) |
|
|
146 |
|
|
|
69 |
|
Total other income (expense), net |
|
$ |
(20,680 |
) |
|
$ |
(382 |
) |
|
$ |
(25,163 |
) |
|
$ |
(1,104 |
) |
Loss before income tax provision |
|
|
(34,441 |
) |
|
|
(1,501 |
) |
|
|
(47,625 |
) |
|
|
(4,723 |
) |
Income tax provision |
|
|
(15 |
) |
|
|
- |
|
|
|
(22 |
) |
|
|
- |
|
Net loss and comprehensive loss |
|
$ |
(34,456 |
) |
|
$ |
(1,501 |
) |
|
$ |
(47,647 |
) |
|
$ |
(4,723 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.36 |
) |
|
$ |
(0.07 |
) |
|
$ |
(1.00 |
) |
|
$ |
(0.22 |
) |
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted |
|
|
96,681,887 |
|
|
|
22,016,451 |
|
|
|
47,421,668 |
|
|
|
21,925,268 |
|
|
||||||||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
114,896 |
|
|
$ |
17,009 |
|
Accounts receivable, net of allowance for doubtful accounts of |
|
|
24,576 |
|
|
|
10,525 |
|
Inventory |
|
|
10,225 |
|
|
|
7,912 |
|
Capitalized transaction costs |
|
|
- |
|
|
|
522 |
|
Prepaid expenses and other current assets |
|
|
7,088 |
|
|
|
1,646 |
|
Total current assets |
|
$ |
156,785 |
|
|
$ |
37,614 |
|
Property and equipment, net |
|
|
1,889 |
|
|
|
1,718 |
|
Intangible assets, net |
|
|
588 |
|
|
|
605 |
|
Internally developed software |
|
|
617 |
|
|
|
- |
|
Other assets |
|
|
398 |
|
|
|
181 |
|
Total assets |
|
$ |
160,277 |
|
|
$ |
40,118 |
|
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Deficit |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
16,460 |
|
|
$ |
16,379 |
|
Accrued and other expenses |
|
|
17,431 |
|
|
|
10,592 |
|
Deferred revenues |
|
|
1,868 |
|
|
|
1,643 |
|
Line of credit |
|
|
11,125 |
|
|
|
9,700 |
|
Current portion of related party convertible notes payable |
|
|
- |
|
|
|
6,934 |
|
Current portion of long-term debt |
|
|
9,435 |
|
|
|
2,024 |
|
Total current liabilities |
|
$ |
56,319 |
|
|
$ |
47,272 |
|
Deferred rent, net of current portion |
|
|
258 |
|
|
|
322 |
|
Long-term deferred revenues, net of current portion |
|
|
206 |
|
|
|
159 |
|
Long-term debt, net |
|
|
9,492 |
|
|
|
10,180 |
|
Preferred stock warrant liability |
|
|
- |
|
|
|
2,993 |
|
Common stock warrant liability |
|
|
17,014 |
|
|
|
- |
|
Other long-term liabilities |
|
|
13 |
|
|
|
13 |
|
Total liabilities |
|
$ |
83,302 |
|
|
$ |
60,939 |
|
Commitments and contingencies (Note 7) |
|
|
|
|
|
|
||
Redeemable convertible Series A and Series A-1 preferred stock, |
|
|
- |
|
|
|
23,652 |
|
Redeemable convertible Series B and Series B-1 preferred stock, |
|
|
- |
|
|
|
23,536 |
|
Stockholders’ deficit: |
|
|
|
|
|
|
||
Common stock, |
|
|
11 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
196,330 |
|
|
|
3,708 |
|
Accumulated deficit |
|
|
(119,366 |
) |
|
|
(71,718 |
) |
Total stockholders’ equity / deficit |
|
|
76,975 |
|
|
|
(68,009 |
) |
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity / deficit |
$ |
160,277 |
$ |
40,118 |
||||
|
||||||||
|
|
Nine Months Ended |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(47,647 |
) |
|
$ |
(4,723 |
) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
799 |
|
|
|
621 |
|
Amortization of debt issuance costs |
|
|
- |
|
|
|
19 |
|
Amortization of debt discount |
|
|
19 |
|
|
|
89 |
|
Non-cash gain on forgiveness of debt |
|
|
(2,098 |
) |
|
|
- |
|
Non-cash loss on extinguishment of debt |
|
|
173 |
|
|
|
- |
|
Loss (gain) on disposal of intangibles |
|
|
7 |
|
|
|
(11 |
) |
Stock-based compensation |
|
|
2,310 |
|
|
|
702 |
|
Write-down of inventory to net realizable value |
|
|
84 |
|
|
|
- |
|
Provision for losses on accounts receivable |
|
|
699 |
|
|
|
20 |
|
Interest expense from contingent beneficial conversion feature |
|
|
26,061 |
|
|
- |
|
|
Change in fair value of common stock warrant liability |
|
|
(5,792 |
) |
|
- |
|
|
Change in fair value of preferred stock warrant liability |
|
|
5,578 |
|
|
|
(9 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(14,750 |
) |
|
|
(2,060 |
) |
Prepaid expenses and other assets |
|
|
(5,000 |
) |
|
|
(590 |
) |
Inventory |
|
|
(2,397 |
) |
|
|
(2,301 |
) |
Accounts payable |
|
|
64 |
|
|
|
8,409 |
|
Accrued and other expenses |
|
|
6,793 |
|
|
|
3,775 |
|
Deferred related party convertible notes payable interest |
|
|
186 |
|
|
|
258 |
|
Deferred revenues |
|
|
272 |
|
|
|
489 |
|
Deferred rent |
|
|
(64 |
) |
|
|
(14 |
) |
Net cash (used in) provided by operating activities |
|
|
(34,703 |
) |
|
|
4,674 |
|
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchase of property and equipment |
|
|
(883 |
) |
|
|
(884 |
) |
Purchase of intangible assets |
|
|
(87 |
) |
|
|
(56 |
) |
Internally developed software |
|
|
(590 |
) |
|
|
- |
|
Net cash used in investing activities |
|
|
(1,560 |
) |
|
|
(940 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from line of credit |
|
|
8,182 |
|
|
|
10,533 |
|
Payments on line of credit |
|
|
(6,757 |
) |
|
|
(11,266 |
) |
Proceeds from issuance of long-term debt |
|
|
5,000 |
|
|
|
1,000 |
|
Proceeds from financed insurance premium |
|
|
5,526 |
|
|
|
637 |
|
Payments on financed insurance premium |
|
|
(1,910 |
) |
|
|
(191 |
) |
Payments for extinguishment of debt |
|
|
(9 |
) |
|
|
- |
|
Payments for cash payout of stock options as a result of the reverse recapitalization |
|
|
(9,890 |
) |
|
|
- |
|
Proceeds from Paycheck Protection Program loan |
|
|
- |
|
|
|
2,075 |
|
Proceeds from exercise of common stock options |
|
|
345 |
|
|
|
87 |
|
Proceeds from reverse recapitalization and PIPE financing, net of |
|
|
133,663 |
|
|
|
- |
|
Net cash provided by financing activities |
|
|
134,150 |
|
|
|
2,875 |
|
Net change in cash and cash equivalents |
|
|
97,887 |
|
|
|
6,609 |
|
Cash and cash equivalents at beginning of period |
|
|
17,009 |
|
|
|
11,736 |
|
Cash and cash equivalents at end of period |
|
$ |
114,896 |
|
|
$ |
18,345 |
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
Cash paid for interest |
|
$ |
538 |
|
|
$ |
337 |
|
Supplemental disclosure of non-cash financing activities: |
|
|
|
|
|
|
||
Conversion of redeemable convertible preferred stock to common stock |
|
$ |
47,182 |
|
|
|
- |
|
Conversion of related party convertible notes to common stock |
|
$ |
33,182 |
|
|
|
- |
|
Warrants received as part of the business combination |
|
$ |
22,806 |
|
|
- |
|
|
Issuance of common stock warrants in connection with debt amendment and new debt issuance |
|
|
- |
|
|
$ |
226 |
|
Unpaid purchases of property and equipment |
|
$ |
- |
|
|
$ |
36 |
|
Unpaid purchases of intangibles |
|
$ |
38 |
|
|
$ |
13 |
|
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Net loss |
|
$ |
(34,456 |
) |
|
$ |
(1,501 |
) |
|
$ |
(47,647 |
) |
|
$ |
(4,723 |
) |
Income tax provision |
|
|
15 |
|
|
|
- |
|
|
|
22 |
|
|
|
- |
|
Interest expense |
|
|
484 |
|
|
|
379 |
|
|
|
1,387 |
|
|
|
1,047 |
|
Interest expense from contingent beneficial conversion feature |
|
|
26,061 |
|
|
|
- |
|
|
|
26,061 |
|
|
|
- |
|
Interest income |
|
|
(7 |
) |
|
|
(2 |
) |
|
|
(9 |
) |
|
|
(37 |
) |
Depreciation and amortization |
|
|
290 |
|
|
|
259 |
|
|
|
799 |
|
|
|
621 |
|
EBITDA |
|
$ |
(7,613 |
) |
|
$ |
(865 |
) |
|
$ |
(19,387 |
) |
|
$ |
(3,092 |
) |
Preferred stock warrant liability adjustment |
|
|
- |
|
|
|
(1 |
) |
|
|
5,578 |
|
|
|
(9) |
|
Common stock warrant liability adjustment |
|
|
(5,792 |
) |
|
|
- |
|
|
|
(5,792 |
) |
|
|
- |
|
Stock-based compensation |
|
|
697 |
|
|
|
248 |
|
|
|
2,310 |
|
|
|
702 |
|
Transaction costs |
|
|
1,279 |
|
|
|
- |
|
|
|
5,306 |
|
|
|
- |
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
- |
|
|
|
182 |
|
|
|
172 |
|
Gain on loan forgiveness |
|
|
- |
|
|
|
- |
|
|
|
(2,098 |
) |
|
|
- |
|
Adjusted EBITDA |
|
$ |
(11,429 |
) |
|
$ |
(618) |
|
|
$ |
(13,901 |
) |
|
$ |
(2,227 |
) |
Net loss margin |
|
|
(109.4 |
)% |
|
|
(7.1 |
)% |
|
|
(60.8 |
)% |
|
|
(8.7 |
)% |
Adjusted EBITDA margin |
|
|
(36.3 |
)% |
|
|
(2.9 |
)% |
|
|
(17.7 |
)% |
|
|
(4.1 |
)% |
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Net loss |
|
$ |
(34,456 |
) |
|
$ |
(1,501 |
) |
|
$ |
(47,647 |
) |
|
$ |
(4,723 |
) |
Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
||||||||
Non-recurring interest expense from contingent beneficial conversion feature |
|
|
26,061 |
|
|
|
|
|
26,061 |
|
|
|
||||
Stock-based compensation |
|
|
697 |
|
|
248 |
|
|
|
2,310 |
|
|
702 |
|
||
Transaction costs |
|
|
1,279 |
|
|
- |
|
|
|
5,306 |
|
|
- |
|
||
Preferred stock warrant liability adjustment |
|
|
- |
|
|
(1 |
) |
|
|
5,578 |
|
|
(9 |
) |
||
Common stock warrant liability adjustment |
|
|
(5,792 |
) |
|
- |
|
|
|
(5,792 |
) |
|
- |
|
||
Loss on extinguishment of debt |
|
|
- |
|
|
- |
|
|
|
182 |
|
|
172 |
|
||
Gain on loan forgiveness |
|
|
- |
|
|
- |
|
|
|
(2,098 |
) |
|
- |
|
||
Adjusted net loss |
|
$ |
(12,211 |
) |
|
$ |
(1,254 |
) |
|
$ |
(16,100 |
) |
|
$ |
(3,858 |
) |
Weighted-average common shares |
|
|
96,681,887 |
|
|
22,016,451 |
|
|
|
47,421,668 |
|
|
21,925,268 |
|
||
Adjusted weighted-average common shares |
|
|
96,681,887 |
|
|
22,016,451 |
|
|
|
47,421,668 |
|
|
21,925,268 |
|
||
Net loss per share |
|
$ |
(0.36 |
) |
|
$ |
(0.07 |
) |
|
$ |
(1.00 |
) |
|
$ |
(0.22 |
) |
Adjusted net loss per share |
|
$ |
(0.13 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.18 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006345/en/
Investors
Westwicke/ICR
Phone: +1.617.877.9641
mike.cavanaugh@westwicke.com
Media
Phone: +1.801.647.0025
jputnam@owletcare.com
Source:
FAQ
What were Owlet's Q3 2021 financial results?
How did Owlet's losses change in Q3 2021?
What is Owlet's current regulatory status for the Smart Sock?
Where has Owlet expanded internationally?
When will Owlet provide its next financial outlook?
